STOCKHOLM, Aug. 18, 2023 /PRNewswire/ — Calliditas Therapeutics AB (Nasdaq: CALT), (Nasdaq Stockholm: CALTX) (“Calliditas”), today announced that the U.S. Food and Drug Administration (FDA) has accepted the submission for the supplemental New Drug Application (sNDA) for TARPEYO®…
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy
This post was originally published on this site